Detection of MboII polymorphism at the 5′ promoter region of CYP3A4

被引：0
|
作者：
Cavalli, SA [1 ]
Hirata, MH [1 ]
Hirata, RDC [1 ]
机构：
[1] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Clin & Toxicol Anal, BR-05508900 Sao Paulo, Brazil
来源：
CLINICAL CHEMISTRY | 2001年 / 47卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：348 / 351
页数：4
相关论文
共 50 条
  • [31] The Relative Contributions of CYP3A4 and CYP3A5 to the Metabolism of Vinorelbine
    Topletz, Ariel R.
    Dennison, Jennifer B.
    Barbuch, Robert J.
    Hadden, Chad E.
    Hall, Stephen D.
    Renbarger, Jamie L.
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (09) : 1651 - 1661
  • [32] Selective expression of CYP3A5 and not CYP3A4 in human blood
    Janardan, SK
    Lown, KS
    SchmiedlinRen, P
    Thummel, KE
    Watkins, PB
    PHARMACOGENETICS, 1996, 6 (05): : 379 - 385
  • [33] Expression and localization of CYP3A4 and CYP3A5 in human lung
    Anttila, S
    Hukkanen, J
    Hakkola, J
    Stjernvall, T
    Beaune, P
    Edwards, RJ
    Boobis, AR
    Pelkonen, O
    Raunio, H
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1997, 16 (03) : 242 - 249
  • [34] CYP3A4*1G regulates CYP3A4 intron 10 enhancer and promoter activity in an allelic-dependent manner
    Yang, Weihong
    Zhao, Dengzhi
    Han, Shengna
    Tian, Zengyuan
    Yan, Liang
    Zhao, Guodiang
    Kan, Quancheng
    Zhang, Wei
    Zhang, Lirong
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (08) : 647 - 657
  • [35] CYP3A5 and not CYP3A4 is present in peripheral blood.
    Janardan, SK
    Lown, KS
    SchmiedlinRen, P
    Watkins, PB
    GASTROENTEROLOGY, 1996, 110 (04) : A1222 - A1222
  • [36] CYP3A4*1G REGULATED CYP3A4 INTRON 10 ENHANCER AND PROMOTER ACTIVITY IN AN ALLELIC-DEPENDENT MANNER
    Yang, W. -H
    Zhao, D. -Z
    Han, S. -N
    Tian, Z. -Y
    Yan, L.
    Zhao, G. -Q
    Kan, Q. -C
    Zhang, W.
    Zhang, L. -R
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 258 - 258
  • [37] Differences in CYP3A4*1G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations
    Du, Jing
    Yu, Lan
    Wang, Lei
    Zhang, Aiping
    Shi, Yongyong
    Li, Xingwang
    Xing, Qinghe
    He, Lin
    Shu, Anli
    Xu, Lingyun
    Xu, Mingsheng
    Feng, Guoyin
    CLINICA CHIMICA ACTA, 2007, 383 (1-2) : 172 - 174
  • [38] Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
    Williams, JA
    Ring, BJ
    Cantrell, VE
    Jones, DR
    Eckstein, J
    Ruterbories, K
    Hamman, MA
    Hall, SD
    Wrighton, SA
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (08) : 883 - 891
  • [39] Differential regulation of the human CYP3A4 promoter in transgenic mice and rats
    Zhang, WS
    Purchio, AF
    Coffee, R
    West, DB
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (02) : 163 - 167
  • [40] Mapping of protein-DNA interactions in the CYP3A4 proximal promoter
    Bombail, V
    Plant, N
    Gibson, G
    TOXICOLOGY, 2001, 168 (01) : 129 - 130
12345